RNAi modulation of placental sFLT1 for the treatment of preeclampsia-Reference-Cited by-同舟云学术

RNAi modulation of placental sFLT1 for the treatment of preeclampsia

Published:2018-11-19 Issue:12 Volume:36 Page:1164-1173
ISSN:1087-0156
Container-title:Nature Biotechnology
language:en
Short-container-title:Nat Biotechnol

Author:

Turanov Anton A,Lo Agnes,Hassler Matthew R,Makris Angela,Ashar-Patel Ami,Alterman Julia F,Coles Andrew H,Haraszti Reka A,Roux Loic,Godinho Bruno M D C,Echeverria Dimas,Pears Suzanne,Iliopoulos Jim,Shanmugalingam Renuka,Ogle Robert,Zsengeller Zsuzsanna K,Hennessy Annemarie,Karumanchi S Ananth^ORCID,Moore Melissa J,Khvorova Anastasia^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Biomedical Engineering,Molecular Medicine,Applied Microbiology and Biotechnology,Bioengineering,Biotechnology

Link

https://www.nature.com/articles/nbt.4297.pdf

Reference69 articles.

1. Stevens, W. et al. Short-term costs of preeclampsia to the United States health care system. Am. J. Obstet. Gynecol. 217, 237–248.e216 (2017).

2. Maynard, S.E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649–658 (2003).

3. Levine, R.J. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672–683 (2004).

4. Heydarian, M. et al. Novel splice variants of sFlt1 are upregulated in preeclampsia. Placenta 30, 250–255 (2009).

5. Young, B.C., Levine, R.J. & Karumanchi, S.A. Pathogenesis of preeclampsia. Annu. Rev. Pathol. 5, 173–192 (2010).

Cited by 144 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protein isoform-centric therapeutics: expanding targets and increasing specificity;Nature Reviews Drug Discovery;2024-09-04

2. Implications of pregnancy on cardiometabolic disease risk: preeclampsia and gestational diabetes;American Journal of Physiology-Cell Physiology;2024-09-01

3. Fetal Therapies – (stem cell transplantation; enzyme replacement therapy; in utero genetic therapies);Best Practice & Research Clinical Obstetrics & Gynaecology;2024-09

4. Targeted lipid nanoparticles to prevent trans-placental passage in the ex vivo human placental cotyledon perfusion model;2024-08-14

5. Two decades of advances in preeclampsia research: molecular mechanisms and translational studies;Journal of Clinical Investigation;2024-08-01